CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.52

27 Oct
2025

0.010

OPEN

$4.55

0.22%

HIGH

$4.74

1,876,345

LOW

$4.45

TARGET
$6.40 41.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 20.1 - 18.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-20.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx28.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-54.8 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-54.37 %
Return on Invested Capital xxxxxxxxxxxxxxx-54.37 %
Return on Assets xxxxxxxxxxxxxxx-50.27 %
Return on Equity xxxxxxxxxxxxxxx-54.37 %
Return on Total Capital xxxxxxxxxxxxxxx-66.43 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-55.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx84 M
Price To Book Value xxxxxxxxxxxxxxx8.91

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx78 M
Research & Development xxxxxxxxxxxxxxx67 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

15/10/2025

1

Speculative Buy

$6.40

41.59%

Bell Potter notes Clarity Pharmaceuticals' Co-PSMA trial showed that 64Cu-SAR-bisPSMA PET/CT detected significantly more prostate cancer lesions than the current standard 68Ga-PSMA-11 PET/CT in men with low but rising PSA levels after surgery.

This earlier and more sensitive detection may improve access to curative treatments such as surgery or radiotherapy, the broker notes. Full patient outcome data is still to come and will likely be outlined at an upcoming medical conference.

The announced results met Bell Potter's expectations and a Speculative Buy rating is retained. Target price lifted to $6.40 from $5.70.

No change to the broker's earnings estimates.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.70 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -15.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

10/10/2025

1

Buy

$9.00

99.12%

Clarity Pharmaceuticals enters the final quarter of 2025 with about $280m in cash, highlights Canaccord Genuity.

The broker also notes there is an important upcoming readout from its Co-PSMA trial comparing 64Cu-SAR-bisPSMA with 68Ga-PSMA-11. These are both radiotracers used in positron emission tomography (PET) scans, in biochemically recurrent prostate cancer.

The analysts expect results by November, viewing the study as a key inflection point which could demonstrate superior detection at lower prostate-specific antigen (PSA) levels, where existing PSMA PET imaging agents often fail.

The broker estimates around 500,000 US patients are underserved, representing a US$5bn addressable market. Positive results could expand this market and strengthen Clarity’s position against competitors Telix Pharmaceuticals, and Lantheus Holdings.

Canaccord retains a Buy rating and $9.00 price target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -26.90 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -34.60 cents.
Access Extra Coverage Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Rudi’s View: In Corporate Earnings We Must Trust

Oct 22 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Oct 10, 2025

Oct 10 2025 - Daily Market Reports
3
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
4
Rudi’s View: Coles, GemLife, Harvey Norman, Lynas, Orica, Reece, Seek & More

Sep 18 2025 - Rudi's View
5
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia